In individuals with type 1 diabetes who test positive for asymptomatic celiac disease, a gluten-free diet may increase postprandial glycemic levels.
The treatment benefits of bariatric surgery in adults are similar regardless of early- or adult-onset obesity.
Adolescents with obesity or type 2 diabetes are at increased risk for progression of cardiovascular risk factors and accelerated early vascular aging.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for setmelanotide for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity.
Dolutegravir-based regimen may lead to significant improvement in lipids blood concentration, but relevant increases in trunk fat without alterations of body mass index.
Upward income mobility is associated with lower perceived stress and fewer depressive symptoms but with higher rates of metabolic syndrome.
Healthcare systems in New York City have partnered to support vulnerable children with obesity using a telehealth weight management program.
Children living with HIV demonstrate deficits in bone architecture and reductions in bone strength, compared with children without HIV.
The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
Researchers presented the outcomes from a 2-year intervention that included bone-strengthening physical activity and dietary behaviors of children attending after-school programs in the United States.
Particular antiretroviral therapy (ART) regimens may decrease bone mass density (BMD) in both adolescents and older people living with HIV (PWHIV).